Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Martin Dreyling, Sebastian Böttcher et al.|Blood|2009Cited by 269
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphomaMarie‐Hélène Delfau‐Larue, Eva Hoster, Wolfgang Hiddemann et al.|Blood|2015Cited by 157